标题:Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials
作者:Qi, Qingqing; Zhang, Yan; Chen, Feixue; Zuo, Xiuli; Li, Yanqing
作者机构:[Qi, Qingqing; Zhang, Yan; Chen, Feixue; Zuo, Xiuli; Li, Yanqing] Shandong Univ, Qilu Hosp, Dept Gastroenterol, 107 Wenhuaxi Rd, Jinan 250012, Shandon 更多
通讯作者:Li, YQ
通讯作者地址:[Li, YQ]Shandong Univ, Qilu Hosp, Dept Gastroenterol, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
来源:BMC GASTROENTEROLOGY
出版年:2018
卷:18
DOI:10.1186/s12876-017-0734-2
关键词:Ramosetron; Irritable bowel syndrome with diarrhea; Efficacy; Safety;; Meta-analysis
摘要:Background: Ramosetron is a potent and selective serotonin type 3 receptor antagonist. This meta-analysis aimed to analyze the efficacy and safety of ramosetron for irritable bowel syndrome with diarrhea (IBS-D).; Methods: Pubmed, MEDLINE, EMBASE and the Cochrane Library were searched for randomized controlled trials investigating the efficacy and safety of ramosetron for IBS-D. Risk of bias was assessed as described in the Cochrane handbook. A random effects model was used to calculate the effects of ramosetron vs placebo on symptomatic improvements, including relief of overall IBS symptoms, relief of abdominal discomfort/pain, improvement in abnormal bowel habits, and improvement in stool consistency, expressed as pooled relative risks (RRs) with 95% confidence interval (CI). Adverse events data were also summarized with RRs.; Results: Four randomized controlled trials involving 1623 participants were included. Compared with placebo, ramosetron could lead to relief of overall IBS symptoms (RR 1.70; 95% CI 1.48, 1.95), relief of abdominal discomfort/pain (RR 1.41; 95% CI, 1.24, 1.59), improvement in abnormal bowel habits (RR 1.72; 95% CI, 1.50, 1.98) and improvement in stool consistency (RR 1.71; 95% CI 1.40, 2.08). Ramosetron could lead to relief of overall IBS symptoms in both male and female patients (RR; 95% CI: 1.94; 1.58, 2.38 and 1.49; 1.25, 1.79). The RR (95% CI) for reported adverse events of ramosetron vs placebo was 1.10 (0.97, 1.26) across all studies. No serious adverse events (e.g., ischemic colitis) were reported. The incidences of hard stool and constipation were higher in ramosetron group compared with placebo group (RR; 95% CI: 4.74; 3.00, 7.51 and 2.53; 1.57, 4.10, respectively).; Conclusions: Ramosetron had beneficial effects to both male and female IBS-D patients. Treatment with ramosetron could cause more hard stool and constipation, without severe adverse events.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040327636&doi=10.1186%2fs12876-017-0734-2&partnerID=40&md5=4e1ff0d57c99e564385b8f71ab30b30a
TOP